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The so-called diabetes ‘annual review’ is an opportunity to check 
that a person with diabetes 
has received elements of care 
such as screening for 
complications and a review 
and revision of their diabetes 
knowledge (Diabetes UK, 
2005a). The aim of review is 
to delay, detect or prevent 
acute and longer term 
complications of diabetes by 
considering metabolic control 
and associated risk factors. 
Those elements of care which 
are recommended for 
inclusion in an annual review 
are identifi ed in Figure 1. 
Targets for carrying out many 
of the measures necessary to 
fulfi l these recommendations 
appear in the Quality and 
Outcomes Framework of the 
new GMS Contract (British 
Medical Association (BMA), 
2008a).
It is important that all 
patients with diabetes consent 
to be included on a practice 
diabetes register so that they 
can be monitored regularly 
(Crumbie, 2002). Anonymized 
data may then be aggregated 
for a district-wide register 
which can be used for 
epidemiological purposes 
(Haynes et al, 2007) such as 
monitoring the prevalence of 
diabetic complications to plan 
for future services.
Structuring a 
diabetes review
A useful guide to ensuring 
that key aspects of diabetes 
care are carried out is the 
alphabet strategy—advice, 
blood pressure, cholesterol, 
diabetes control, eyes, feet, 
guardian drugs (Patel and 
Morrissey, 2002) (Figure 2). 
This strategy could be 
perceived as somewhat 
prescriptive rather than 
patient-centred, and some 
parameters have been changed 
since it was fi rst introduced, 
but the mnemonic aids the 
focus on key interventions to 
reduce cardiovascular, renal, 
retinal and foot 
complications. Guidelines 
from the National Institute 
for Health and Clinical 
Excellence (NICE) (2008) 
recommend aiming for a 
systolic blood pressure of 
<130 mmHg where there are 
signs of target organ damage 
and total cholesterol 
<4.0 mmol/litre. Advising 
patients to reach such targets 
could be considered out of 
step with a patient-centred 
approach, and it might be 
more appropriate and effective 
to ‘agree’ a plan of care.
Care planning is part of a 
patient-centred approach that 
facilitates a more active role 
by patients in the 
management of their diabetes. 
It allows the person with 
diabetes to make more 
decisions on the care he/she 
receives in collaboration with 
a health professional who is 
practising a partnership 
approach (Department of 
Health (DH), 2006; National 
Diabetes Support Team 
(NDST), 2008). Some of the 
core principles of this 
approach require clinicians to 
set aside the ‘professional 
expert’ to become a facilitator 
who uses a more behavioural 
approach to consultation 
(Tomkins and Collins, 2006). 
Using this approach John 
would be encouraged to share 
and discuss information and 
negotiate goals and agendas 
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Annual assessment
Exploration of any concerns
Assessment of ability to self-care
Review of metabolic control
HbA1c and blood glucose monitoring; episodes
of DKA and hypoglycaemia; dietary assessment
Identifi cation and management of
cardiovascular risk factors
Monitoring physical growth
Measurements of height and weight
Surveillance for long-term 
Identifi cation and management of
other problems
Depression, skin problems, etc
Regular reviews
Continuing education and exploration
of concerns
Review of metabolic control and
menagement options
Agree revised
care plan
Education, 
support
Advice on
healthy life 
Advice on
clinical options
Referral for 
specialist
Figure 1. Elements of a diabetes review (Diabetes UK, 2005b)
Advice: exercise, diet, not
smoking, regular testing
and clinics
Blood pressure: aim less
than 140/80 mmHg
Cholesterol: less than 5
Diabetes control: HbA1c
7% or less (amount of
glucose sticking to your
blood over the last two
months)
Eyes: check yearly at least
Feet: check yearly at least
Guardian drugs: aspirin
75 mg protects against
heart disease
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Figure 2. The alphabet strategy: a person-centred approach to care 
planning.
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with the nurse (DH, 2006) 
(Case Study). 
A simple strategy for 
helping people with diabetes 
prepare for a review and gain 
more from it is to post their 
results to them in advance. A 
leafl et that lists the parameters 
for each metabolic measure, 
explains what each means, 
and gives the patient space to 
write down why the results 
might not meet preset goals 
can be useful (NDST, 2008) 
(Figure 3). This approach 
might help John consider why 
his blood glucose and blood 
pressure are higher than ideal 
before his consultation. The 
practice nurse can support 
John in identifying which 
lifestyle factors he might want 
to address to improve his 
metabolic results. It is 
encouraging that he has had 
some previous success in 
stopping smoking, and the 
nurse can help John build on 
this to make further changes 
he feels he can achieve.
Cardiovascular risk
Cardiovascular disease is 
responsible for 65% of all 
deaths in people with 
diabetes, and micro-
albuminuria is regarded as a 
marker for this (Garg and 
Bakris, 2002). Furthermore, 
John is hypertensive and has 
dislipidaemia, putting him in 
a higher risk category. While 
lifestyle changes are regarded 
as a key strategy for helping 
reduce cardiovascular risk 
(Centers for Disease Control 
and Prevention (CDC), 2005) 
and John may choose to 
consider changes to his diet or 
increase his activity level, he 
will require optimization of 
his angiotensin-converting 
enzyme (ACE) inhibitor 
medication. In the MICRO-
HOPE study of over 3500 
people with diabetes (HOPE 
Investigators, 2000), those 
who were treated with an 
ACE inhibitor (ramipril) had 
their cardiovascular risk 
reduced by 25–30%. 
Furthermore, an ACE 
inhibitor was found to be 
renoprotective and reduce the 
need for laser therapy for 
diabetic retinopathy (HOPE 
Investigators, 2000). 
Patients with type 2 
diabetes and persistent 
microalbuminuria should 
have a target blood pressure 
Figure 3. A sample results sharing sheet for care planning (National Diabetes Support Team, 2008).
John Sykes, a 62-year-old plumber, is visiting 
the practice nurse for a review of his diabetes 
care. John was diagnosed with type 2 diabetes 
7 years ago and has missed his last two 
appointments owing to work commitments. 
His biometric data are shown in Table C1. He 
is being treated with metformin 500 mg three 
times daily, gliclazide 80 mg twice daily, and 
(for blood pressure) lisinopril 10 mg daily. 
John has recently had his annual retinal 
screen which reveals some background 
retinopathy and he is concerned about losing 
his sight. He has forgotten to bring his blood 
glucose testing diary and meter but admits 
he only tests when he remembers and usually 
just before a clinic appointment. 
John’s weight has increased since his last 
visit. He says he now has to wear a belt to 
keep his trousers up below his stomach. He 
thinks this is probably because he gave up 
smoking 6 months ago.
CASE STUDY
Haemoglobin A1c (HbA1c)  8.6%
Blood pressure  152/90 mmHg 
Lipids: 
 • Total cholesterol  5.5 mmol/litre
 • Low-density lipoprotein  2.8 mmol/litre
 • High -density lipoprotein 0.8 mmol/litre 
 • Triglycerides  2.3 mmol/litre
Microalbuminuria  8.3 mg/mmol
(albumin creatinine ratio)
Estimated glomerular fi ltration rate NA
Body mass index 32 kg/m2
Table C1. John’s biometric 
data
 Your result was Comment
Diabetes control
Your HbAlc is an overall measure of glucose control HbAlc 6.6% This shows good control but you are getting sugars frequently
over the past 8–10 weeks. A level of between 6 and 7%  below 4 in the morning. We agreed to reduce your evening
is associated with the lowest risk of complications.  Glicazide to 40mg (half a tablet) or perhaps even stop it.
Blood pressure (BP)
A target blood pressure of below 130/80 lowers the risk BP 125/72 Excellent
of complications (a target of below 125/75 is used if
you have kidney disease).
Cholesterol and blood fats
Lowering your cholesterol can reduce the risk of Cholesterol 4.2 Excellent
complications such as heart attacks and strokes.
Whether or not you need treatment depends on your
overall risk. If you are on treatment the target
cholesterol is less than 5.
Kidney tests
Your kidneys are tested by looking at a blood test Creatine 146 Your creatinine is dlightly high (eGFR 45) but this has been
(creatinine) and the leak of protein in your urine. Urine: Normal stable since at least 2001. I explained this does demonstrate
  some damage to the kidneys but suggested I was not too
  worried about this at the moment.
Weight & body mass index
Being overweight increases the risk of many medical Weight 104.6kg We discussed this in some detail today and used the action
conditions including heart disease, arthritis and BMI 34.95 planning approach sheet. You have already made some
premature death. It can also make your diabetes and  changes such as cutting down portion sizes and avoiding fatty
blood pressure more diffi cult to control. The body mass  foods which seem to be working (you have lost some weight
index (BMI) is another way to look at your weight by   since the last appointment). You are quite confi dent you will be
adjusting for your height. A BMI between 19 and 25 is   able to keep these up.
associated with the lowest risk to your health
Smoking
Smoking causes problems with your health in many ways You are an Excellent
but is particularly damaging in people with diabetes. ex-smoker
              Name:                                       Date of Birth:                                               Date sheet completed:
Practice Nursing 2009, Vol 20, No 1 21
 
of <135/75 mmHg (NICE, 
2006). Consequently, the 
benefi ts of increasing John’s 
lisinopril to a maintenance 
dose of 20–40 mg (Joint 
Formulary Committee, 2008) 
should be discussed with him. 
Any increase in ACE inhibitor 
should be followed by an 
assessment of renal function 
(NICE, 2006).
Microvascular risk
John is right to be concerned 
about his vision as diabetes is 
the most common cause of 
blindness in people of 
working age (Bunce and 
Wormald, 2006). The United 
Kingdom Prospective Diabetes 
Study (UKPDS) (1998a, 2000) 
reported on improvements in 
outcomes for patients who 
maintained good control of 
both blood pressure and 
blood glucose. John has 
already been identifi ed as 
having changes in his retina 
as a result of his eye 
screening. Although he does 
not require photocoagulation 
at this stage, it is important to 
treat hypertension and 
hyperglycaemia which will 
accelerate eye disease. If his 
blood pressure and albumin-
creatinine ratio (ACR) 
improves with titration of his 
lisinopril then from a 
comparatively modest change 
to his medication he is 
reducing the risk of eye, 
kidney and heart disease. 
However, it is important to 
observe that for many 
patients more than one 
antihypertensive may be 
required, along with lifestyle 
changes, to reduce blood 
pressure (NICE, 2006).
Communicating risk
Usher (2008a) proposes that 
cultural and personal beliefs 
may play a signifi cant part in 
how patients perceive risk. 
Patients may ascribe health 
risk to ‘immutable 
circumstances’ whereas other 
factors may be far more 
signifi cant, particularly if it is 
possible to stimulate greater 
awareness and provide ‘clear 
information’. 
As John is concerned about 
his vision he may be more 
motivated to improve control 
of his blood glucose and 
blood pressure if he 
understands the mechanisms 
of how diabetic eye disease 
can develop and how he can 
reduce the longer term risk of 
loss of vision.
A quantifi able method of 
measuring behaviour change 
might help address 
cardiovascular risk. 
Explanations of 
cardiovascular risk can be 
complex and may not lead to 
behaviour change. 
Information that is presented 
in the format of a 
cardiovascular risk calculator, 
for example, may help, 
particularly if accompanied 
by simple explanations 
(Goldman et al, 2006). 
The UKPDS Risk Engine 
(Diabetes Trials Unit, 2001) 
(Figure 4) is a tool which may 
be downloaded and used to 
help with the management of 
people with type 2 diabetes in 
calculating cardiovascular risk 
(Stevens et al, 2001). Indeed 
NICE (2008) advocates using 
the UKPDS Risk Engine to 
calculate cardiovascular risk 
annually. This might be a 
crude measure of risk 
reduction, but it may appeal 
to John if the nurse can 
recalculate reductions in risk, 
for example, by entering a 
target for lowering his 
cholesterol or blood pressure.
In view of John’s age, 
history of diabetes and risk of 
vascular disease, he may 
experience erectile 
dysfunction. This can have a 
profound effect on self-
esteem, mood and on 
relationships. About 50% of 
men with diabetes may 
experience some problems 
with erectile dysfunction and 
many may not volunteer this 
unless asked (McCoid, 2007). 
Sensitive questioning may 
provide the opportunity for 
John to respond so that he 
can be assessed and receive 
appropriate treatment which 
is likely to be an oral 
medication such as sildenafi l 
(NICE, 2008). 
It is important to ask John 
if he has any problems with 
his feet, get him to remove his 
shoes and socks and for the 
nurse to carry out a neuro-
vascular assessment (NICE, 
2004). Further training may 
be required in the use of a 
monofi lament and foot 
assessment and use a simple 
clinical algorithm such as the 
Tayside Clinical Risk Tool to 
stratify risk (Leese et al, 
2006). The nurse should ask 
John to talk through how he 
might examine his own feet 
and what he would do if he 
thought he had any problems 
(NICE, 2004).
The onset of complications 
can be linked with low mood, 
and depression is twice as 
common in those with 
diabetes and often goes 
undiagnosed and under-
treated (Snoek and Skinner, 
2006). Depression can also 
disrupt glycaemic control 
(Snoek and Skinner, 2006). A 
simple screen for depression is 
part of the Quality and 
Outcomes Framework (BMA, 
2008) and may help identify 
patients who require further 
support or services.
The value of 
self-monitoring 
John has indicated his 
reluctance to test his blood 
glucose and there may be 
good reasons for this, 
particularly if readings are 
higher than he would prefer, 
if he receives no feedback on 
his results when he attends 
clinic, of if he does not know 
Figure 4. The UKPDS Risk Engine (available at www.dtu.ox.ac.uk/index.
php?maindoc=/riskengine/)
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how to use results to help him 
manage his diabetes 
(Davidson, 2005; Peel et al, 
2007). Furthermore, he may 
be reluctant to test due to 
pain, inconvenience 
(especially at work) or feeling 
self-conscious (Peel et al, 
2004; Hadley-Brown et al, 
2008). Guidance suggests that 
self-monitoring of blood 
glucose may benefi t some 
people with diabetes (Owens 
et al, 2004). However, Simon 
et al (2008) concluded that 
self-monitoring may increase 
anxiety in people with type 2 
diabetes, having a negative 
impact on quality of life, and 
not being cost-effective for 
routine use. 
However, asking if John 
would test his blood glucose 
levels for short periods, for 
example, while his HbA1c 
remains above target and 
teaching him to monitor any 
changes to treatment or 
lifestyle may be more 
acceptable. It might also be 
useful for him to test if he is 
experiencing any unusual 
symptoms, such as dizziness 
or shaking, which might 
relate to a low blood glucose 
level with a sulphonylurea 
(Hadley-Brown et al, 2008). 
Self-monitoring of blood 
pressure may be imposing an 
additional burden on him and 
it is probably more important 
to help him to continue with 
his medication. 
Medication review 
Raynor (1998) advises that 
those taking prescribed 
medicines require suffi cient 
information to: 
Enable them to take and 
use the medicines 
effectively
Understand the relative 
risks and benefi ts, to allow 
➤
➤
them to make an informed 
decision about taking them. 
However, Raynor (1998) 
points out that providing 
information does not always 
result in a transfer of 
knowledge, nor does 
knowledge transfer necessarily 
result in a change in 
behaviour or attitude. It is 
important to have an open 
dialogue with John about 
how and when he takes his 
medications. Ensuring 
patients take their current 
medicines before making any 
changes to doses or adding in 
additional therapies is 
important. 
Adherence to prescribed 
medications can be 
suboptimal, particularly 
antihypertensives, with as 
many as 50% of patients 
abandoning treatment 
altogether after a year or 
taking ‘drug holidays’ for 
single doses or for several 
days (Vrijens et al, 2008). 
Diabetes UK (2008) has 
reported that as many one in 
fi ve people with diabetes are 
not taking their medications 
and lacked knowledge about 
the cardiovascular risks 
associated with type 2 
diabetes. 
It might be useful to fi nd 
out about John’s 
understanding of his 
medication, including timing 
of doses, whether he forgets 
or omits his tablets and has 
any problems taking them, in 
addition to his knowledge of 
the potential risks of having 
diabetes and hypertension. 
Beliefs may also have a key 
role in adherence. Negative 
perceptions related to side 
effects (e.g. weight gain with 
sulphonylureas) and changes 
to daily routine which made 
taking medications more 
diffi cult were signifi cant 
predictors of nonadherence in 
a study by Farmer et al 
(2006). Measures such as 
once-daily doses, combination 
therapies and the use of tablet 
dispensers may help patients 
take their medications 
appropriately (Goldie, 2006).
Guardian drugs
Metformin was shown to 
have a positive effect on 
cardiovascular disease in the 
UKPDS (1998b), reducing the 
risk of myocardial infarction 
by 39% and stroke by 41% 
compared with intensive 
treatment with other agents. 
John could have a modifi ed-
release form so that he has 
fewer tablets to take and does 
not have to remember to take 
them at work, a trade-off 
which might encourage him 
to take his medications 
(Usher, 2008b). Increasing the 
dose of metformin, which has 
a neutral effect on weight, 
and stopping the 
sulphonylurea, which causes 
weight gain, may help with 
John’s blood glucose control 
if he can change his diet or 
increase his activity levels. 
To counteract 
hypercoagulability, which is a 
feature of the metabolic 
syndrome in type 2 diabetes 
and increases the risk of 
vascular events (Nugent, 
2005), low-dose aspirin 
(75 mg) is recommended. 
John’s cholesterol is elevated, 
and while he could consider 
improvements to his diet, such 
as reducing saturated fats or 
taking plant sterols in dairy 
products such as spreads and 
yoghurts, it is likely he will 
benefi t from a statin, e.g. 
simvastatin 40 mg, to be 
taken in the evening; statins 
work most effectively 
overnight (NICE, 2008).
Conclusions
While regular surveillance for 
complications is 
recommended by the National 
Service Framework for 
Diabetes (DH, 2001), the 
consultation should also be an 
opportunity for the person 
with diabetes to discuss areas 
of concern including 
psychological, emotional and 
social wellbeing (Jerreat, 
2003), culminating in a 
negotiated plan of care with 
jointly negotiated goals for 
the future. These may be 
reviewed at 3–6 months or 
more frequently during an 
interim consultation, 
depending on the individual’s 
needs or for monitoring 
purposes such as a blood 
pressure check (NICE, 2008). 
Nurse-led risk reduction 
services for people with type 2 
diabetes have had positive 
evaluations (Denver et al, 
2003; Woodward et al, 2005) 
and there are good examples 
of strategies that help engage 
with patients in the 
management of risk. 
Furthermore, there is 
accumulating evidence to 
support continuity of care, 
consistent with primary care 
diabetes clinics, including 
increasing patient satisfaction, 
better use of resources and, 
most important, improved 
adherence to treatment (van 
Servellen et al, 2006).
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